The ISSCR is disappointed with the enactment of the ‘Right to Try’ law. Along with more than 100 patient and research groups opposing the bill, we believe it will put patients at risk and undermine the effective FDA Expanded Access Program already in place to give seriously ill patients access to experimental treatments.Full story
- 4 June, 2018
Scientific progress requires that legislators and regulators around the world recognize and appreciate the value of research and actively support pro-science policies. The ISSCR, through its policy program, champions the advancement of stem cell research and its translation to medicine.Full story
- 7 May, 2018
Message from the President
Hubrecht Institute, the Netherlands
Expanding Impact of Stem Cell Science
We have seen important advances in stem cell science in recent years, many the result of new technologies and applications that are propelling research forward and collaborations that are moving science closer to the clinic. Just in the past year, several significant studies such as a trial using a stem cell-based therapy to treat epidermis bullosa, and retinal therapy using stem cells, have shown initial success, with trials in other areas beginning to get underway.
The ISSCR’s role has perhaps never been more important than it is today in advocating for stem cell science and research and in supporting our members, who are committed to delivering on the potential of this evolving field.
stem cell researchTake a closer look
Stem Cells as Anti-Cancer Vaccines?
Vaccines are routinely used to increase immunity against a variety of infectious diseases, such as influenza, measles, and chicken pox, to name a few. Rather than vaccinating against viral infectious diseases, however, imagine a vaccine that could prevent cancer.
Researchers have long been interested in developing a vaccine that can help the body’s immune system and fight abnormal, cancerous cells.
Stem Cells in the News
Media highlights in the field of stem cell research and its translation to the clinic.
8 June, The Atlantic
2 June, Xinhua Net
2 June, Interesting Engineering
29 May, The Mercury News
A sampling of recent stem cell research commentaries, articles, and resources.
On the cover: An artistic illustration of a goddess intervening to control the surrounding tornadoes by causing lightning strikes and a drug rainfall. Related to paper on mapping of a genetically encoded voltage indicator to study drug-induced electrophysiological effects and arrhythmia mechanisms.
Featured Current Protocols in Stem Cell Biology Article
Stem Cell–Derived Retinal Pigment Epithelial Layer Model from Adult Human Globes Donated for Corneal Transplants Marie, F., Brian, M., Lauren, S. and A., B. T. (2018).Current Prot. Stem Cell Biology, 0, E53.
Self-organization and progenitor targeting generate stable patterns in planarian regeneration. Atabay, K. D., LoCascio, S. A., de Hoog, T., and Reddien, P. W. (2018), Science, 360, 404-409.
- , Melbourne
Seeking a job? Have a job opening? the ISSCR Job Board gives members discounts on job postings here and in the monthly Pulse e-newsletter.
Other Stem Cell Events
Opportunities for researchers from around the world to explore the latest discoveries in stem cell science and regenerative medicine.
- , Barcelona
Stem Cell CoursesView All
- , Cambridge
ISSCR and policy news from around the world.
7 June, Science Business
European Commission Publishes its €94.1B Horizon Europe Proposal
Stem Cell Therapy: Is it the Miracle Cure that it Claims to Be?
Learn about ISSCR colleagues in the stem cell field from around the world.
Nils Pfaff, PhD
What is the current focus of your research, and what do you find most rewarding about your work?
I am currently working in preclinical research in the Pharmaceuticals Division of Bayer. Apart from establishing iPSC-derived cells for target identification and validation, the main focus is in vivo pharmacology mostly in the therapeutic areas thrombosis and hemophilia. I really like the application-driven way of working in the (pharma) industry. It is great being involved in projects that always have the goal to improve the life of patients and being able to actually move these projects forward. It’s also fascinating to see how complex developing a new drug actually is and there is something new to learn every day.
What led you to become a scientist and to stem cell research?
I’ve always been interested in science. Back in high school I participated in a science club, which allowed me to work on smaller projects in a university lab during some of the vacations. At first I decided to study medicine but somehow realized I didn’t want to become a physician. That’s why I enrolled for Molecular Medicine (at Göttingen University, Germany), which turned out to be a great combination of science and medicine. When I started my PhD in 2008, iPS cells really were the hottest topic in biomedical research and the possibility to turn a skin cell into a stem cell into a blood/neuronal/cardiac cell was (and still is) just thrilling.
How do you spend your free time?
I regularly play football (soccer for the US folks…) and force myself to go running at least once a week. I also enjoy cooking (end eating, of course) a lot and have become a bit of a wine geek lately as well. Trying to stay in touch with friends and family is also very important for me.
What is something your peers would be surprised to learn about you?
I am a guitarist in a heavy metal band (the long hair is gone, though…) and regularly go to metal concerts and festivals.
What do you most value about your membership with the ISSCR?
Being member of the ISSCR is the best and easiest way to stay connected with the entire stem cell community and to permanently keep track of this still rapidly evolving field. Going to the annual meetings is always fun because you meet colleagues you haven’t seen for a whole year in most of the cases. Of course, the science presented is fascinating every time. Working in the ISSCR Industry Committee is a great way to discuss the industry’s perspective on translational aspects with the community – I think this dialogue is essential to bring effective stem cell-based therapies to patients.